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Introduction
Leprosy is the complex disease manifestation ofMycobacterium leprae infection. Although
prevalence has declined from 5.2 million globally in the 1980s, new annual case detection rates
(CDRs) remain high, at more than 200,000 new cases per year [1], indicating that additional
leprosy control strategies are required to halt transmission.
An Expert Meeting held in June 2013 in Geneva discussed strategies to transition from con-
trol to elimination and concluded that any viable programme would need to include: (i) early
diagnosis and prompt multidrug therapy (MDT) for all patients, (ii) tracing and postexposure
prophylaxis (PEP) for contacts of newly diagnosed patients, and (iii) strict epidemiological sur-
veillance and systems to monitor progress [2]. Improved diagnostic tools would be of great
value to achieve these goals.
A subsequent international Expert Panel met, with the goal to define the required attributes
of a diagnostic test for leprosy that would support and facilitate leprosy elimination efforts in
terms of complete interruption of transmission ofM. leprae. A tool for identifying leprosy
cases (asymptomatic and any symptomatic form of leprosy) was identified as a prerequisite to
elimination, thereby addressing the goals of the 2020 London Declaration on Neglected Tropi-
cal Diseases [3,4]. However, given the challenges of developing such a diagnostic test, a two-
step strategy, starting with a confirmatory test for clinical diagnosis among symptomatic
patients, was considered as a pragmatic approach. This article presents the considerations, tar-
get population, target profile, and current research activities for leprosy diagnostic tools from a
user’s perspective.
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Considerations for Development and Distribution of a Leprosy
Field Test
Currently, leprosy is mainly diagnosed by expert clinicians using defined criteria, along with
the use of slit-skin smears and biopsies [5]. As the prevalence of the disease is decreasing, clini-
cal expertise is diminishing, leading to extended delays between onset of clinical signs and diag-
nosis and consequent maintenance of transmission ofM. leprae. Hence, efforts to achieve
elimination are undermined. In recognition of the need to move from leprosy control to pre-
venting infection, an ideal test would identifyM. leprae-infected individuals at risk of develop-
ing disease and/or who contribute to transmission. However, given the challenge of developing
such a test in the absence of a gold standard, a two-step approach could prove to be a more
expeditious strategy: first, obtaining a test to help health care workers in their clinical diagnosis
and decision-making process for treatment while, over a longer term, another test to identify
infected individuals would be developed. As part of the requirements, two intended uses (IU)
for the tests were defined, based on end-user requirements (Table 1).
Additionally, diagnostic tests should respond to identified needs and consider: (1) endorse-
ment by stakeholders as a requirement to progress to elimination, (2) adding value to current
leprosy programmes, (3) providing direct benefit to the users through accuracy and perfor-
mance in the target population, and (4) being user-friendly to allow application at point of
health care or community levels.
Target Population for a Leprosy Diagnostic Test, Considering
Assay Specificity and the Positive Predictive Value of the Results
Receiving a leprosy diagnosis bears significant social implications related to stigma and medical
implications due to the long treatment duration. Therefore, deploying a diagnostic test (for
IU1 or IU2) that is not perfect requires a coherent strategy to manage positive results. An
example of recommendations for programme guidelines is defined in Table 2.
In low-prevalence settings, for any test not 100% predictive, it is likely that most positives
will be false positives. Therefore, to improve the predictive value, high-risk groups, such as skin
clinic attendees or household contacts, need to be identified and targeted for testing.
Table 3 estimates the positive predictive value (PPV) of true leprosy in high-risk settings,
although the proportion of false positives would depend on the proportion of people actually
infected.
Alternatively, a two-step approach could be considered, whereby an initially high sensitivity
test of at least 95% is followed by a highly specific test of95%, targeting high-risk populations
to minimise false positives.
How Assay Sensitivity May Impact the Elimination Target
Based on SIMCOLEP (individual-based mathematical model), analyses targeting household
contacts have shown that the effects on disease incidence in the whole population vary with
type of intervention, such as contact tracing, provision of chemoprophylaxis, Bacillus Calm-
ette-Guerin (BCG) vaccination, and early (preclinical) diagnosis [6]. The model has been
developed to include the indirect effect of interventions targeting contacts on the transmission
ofM. leprae in the whole population [7].
Using the same model, different scenarios were explored for an IU2 test with a range of sen-
sitivities (specificity does not impact transmission) as a tool for achieving elimination, using
data based on a representative population [8]. Two different approaches to testing—total popu-
lation and contact surveys—were analysed with different endemicity levels (new case detection
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rate [NCDR]: 25, 5, and 1 per 100,000), and additionally, one or two surveys (with a two-year
interval) were modelled for the total population.
Comparing the impact of continuous contact testing with a one-time total population sur-
vey, along with the subsequent treatment of test-positive individuals, results suggested that
NCDR would be more quickly reduced by a one-time population survey. Increasing sensitivity
had an inverse relation to the NCDR. These preliminary results suggest that the optimal strat-
egy is to consecutively test and treat, and a single-survey approach with a test sensitivity of at
least 90% would be sufficient to reach elimination. After a single survey, elimination is reached
after about ten years, and after two surveys, elimination is reached between five and ten years;
in a two-survey approach, test sensitivities of 90%, 80%, and even 70% appear sufficient to
reach elimination. Because of the numbers needed to be tested, and not taking into consider-
ation the poor PPV for disease, a population survey approach is only favourable in a highly
endemic situation.
Programme Consideration and Different Diagnostic Test Devices
Suitable for Leprosy-Endemic Areas
High-risk populations have been identified as an optimal target for a diagnostic test. This
would require national leprosy programmes to intensify their surveillance systems in order to
trigger prompt and targeted testing of high-risk clusters. Individual geographic information
and spatial analysis have already been evaluated to define spatiotemporal patterns of leprosy
[9], but they would need to become integrated into systematic national surveillance systems,
requiring substantial investment. Introducing a new diagnostic test with IU2 could certainly
help to achieve leprosy elimination, but it would require a strong commitment from policy
makers and donors.
Point-of-care, noninvasive tests need to be considered for leprosy diagnostics—ideally, a
rapid lateral flow qualitative (positive or negative) test using capillary blood or urine and includ-
ing one or several test analytes. Other types of testing devices, depending on the selected diag-
nostic marker, could also be considered, such as the host nucleic acid amplification test (NAAT)
[10], which proved to be a promising diagnostic tool for tuberculosis [11,12]. However, such
tests would require further “engineering” research to develop testing platforms that provide an
accurate quantitative readout, e.g., devices to test skin sensitivity, hydration measurement
Table 2. Recommendations for the deployment of a diagnostic test that is not 100% specific.
• Target high-risk groups (for example, contacts of new cases)
• Deﬁne clear educational messages for those tested, including the meaning of test positivity
• Continue observation, clinical examination, and management for test-positive subjects
• Provide MDT for subjects who meet the diagnostic criteria based on clinical signs and symptoms
• Deﬁne optimal short-term treatment for test-positive, asymptomatic subjects
doi:10.1371/journal.pntd.0004331.t002
Table 1. Intended Use statements for a leprosy diagnostic test.
INTENDED USE I (IU1): A leprosy diagnostic test designed to act as an aid in the diagnosis of
symptomatic patients for whom the health care worker requires an
independent diagnostic assessment
INTENDED USE 2 (IU2):
Ideal test
An M. leprae test designed to diagnose individuals who have been infected
with M. leprae and are destined to have clinical symptoms (asymptomatic
person at risk of developing leprosy and sustaining transmission of M.
leprae)
doi:10.1371/journal.pntd.0004331.t001
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devices, or portable ultrasound devices to measure the size of nerves. Innovative methods of
combining different tests may allow higher sensitivity and specificity to be achieved.
As the diagnostic test will be novel, manufactured, and distributed, the tool and any related
instrumentation or software will require regulatory review in accordance with the country
where it will be used. A successful launch will need political commitment for test recommenda-
tion and integration into health care systems, and appropriate training of end users will be
vital, given the implications of a positive test result.
Target Product Profile of a Leprosy Diagnostic Test
The required attributes for the two IUs of a leprosy diagnostic test, derived mainly from the
results of the discussion in the meeting, are summarised in Table 4. The test would diagnose
both Multi-bacillary (MB) and Pauci-bacillary (PB) forms of leprosy [5].
Biomarkers for Leprosy
A review of leprosy biomarkers reveals that the ideal diagnostic biomarker is not currently
available to fulfill the requirements of the target product profile [13]. Past and ongoing research
Table 3. Example of positive predictive values (PPV) of a leprosy diagnostic test.
Sensitivity 75% Reference clinic attendees Household contacts
Speciﬁcity 95% (2% with leprosy) (<1% with leprosy [5])
Leprosy No. leprosy PPV Leprosy No. leprosy PPV
Diagnostic test results
Pos 150 490 23.4% (95% CI 20.2, 26.9%) 15 100 13.4% (95% CI 7.5, 20.6%)
Neg 50 9,310 5 1,900
TOTAL 200 9,800 20 2,000
doi:10.1371/journal.pntd.0004331.t003





Target population: Patients with any skin lesion or peripheral
neurologic defect
Leprosy suspects
Sensitivity %: 90 75
Speciﬁcity %: 95 80
Sample: Whole blood capillary sample Skin, image, whole blood, or serum
sample
Results: Qualitative Quantitative
Device: Lateral ﬂow rapid diagnostic test (RDT) Portable point of care device
Intended Use 2: Ideal
Target population: Total population in endemic areas (high-
risk population)
At-risk individuals (i.e., contacts of
leprosy patients)
Sensitivity %:  90 70
Speciﬁcity %: > 95 90
Sample: Whole blood capillary sample; urine Whole blood, serum, or other body
ﬂuid
Results Qualitative Quantitative
Device: Lateral ﬂow (RDT) Portable point of care device
doi:10.1371/journal.pntd.0004331.t004
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is covering markers for different ends of the leprosy spectrum. Lepromatous Leprosy (LL/BL)
is characterised by a very robust antibody response, whereas Tuberculoid Leprosy (TT/BT) is
characterised by hardly any humoral immunity but much stronger cellular immunity. In addi-
tion,M. leprae-infected individuals without disease symptoms may vary in their biomarker
profile [14,15]. Both cellular and humoral immunity againstM. leprae determine the outcome
of infection. Thus, tests that simultaneously detect biomarkers specific for both types of
immune responses are the targets for a test for detection of asymptomaticM. leprae infection
and hence progression of infection to clinical disease [16].
Two previously characterisedM. leprae antigens, leprosy IDRI diagnostic-1 (LID-1) and
ND-O-BSA, appear to have utility and have been combined as a possible biomarker for LL/BL
leprosy (NDO-LID) [17]. Serum antibody responses in leprosy patients correlated with the
bacteriological index and Ridley–Jopling categorisation. LL/BL leprosy patients were distin-
guished with a high degree of sensitivity (95.7%) and specificity (93.2%). Additionally, the
NDO-LID serological test has been shown to detect slightly larger proportions of BL/LL and
TT/BT leprosy than the serology leprosy test detecting Immunoglobulin M (IgM) antibodies to
M. leprae-specific phenolic glycolipid (PGL-I) (87.0% versus 81.7% and 32.3% versus 6.5%,
respectively), and it also demonstrated improved specificity [18]. Use of these antigens in rapid
test formats, coupled with a simple test reader platform, can provide consistent, objective, and
quantifiable assessment, potentially facilitating wider use in nonspecialised settings. However,
this assay does not or only weakly detects TT/BT individuals, similar to the anti-PGL-1 IgM
antibodies, which is usually around 20%–40%.
In addition to humoral immunity, severalM. leprae proteins and peptides have been identi-
fied as specific targets for cellular immunity againstM. leprae [19, 20, reviewed in 21], some of
which are currently used to measure the level of exposure toM. leprae [14] and thus the risk of
infection and subsequent disease. Furthermore, extended investigations on cellular immune
response [14] as well as genetic host biomarkers [9] are under investigation in current field tri-
als [22], allowing future development of improved immunodiagnostic assays in terms of sensi-
tivity and operational and sampling requirements [23,24].
Promising results have been obtained using different approaches such as serological meta-
bolomics to unravel the biological pathways involved in the immunomodulation of leprosy
[25]. Also, pathogen-based approaches have been explored, aimed at the development of assays
forM. leprae detection [26]. Besides their use for diagnostic purposes, it is of note that new bio-
marker discovery approaches for leprosy also contribute to our understanding of its immune-
pathologic mechanisms and will aid in the identification of therapeutic interventions.
Conclusion
In conclusion, in the absence of a perfect test to detect allM.leprae-infected individuals, a diag-
nostic test to confirm leprosy disease at an early stage among symptomatic patients would be
an acceptable and certainly useful shorter-term compromise. In parallel, it is critical that stake-
holders continue promoting the concept that zero transmission is only attainable ifM.leprae
infection can be measured, and correspondingly invest in longitudinal research to identify bio-
markers for the diagnosis of asymptomatic infection as well as for the risk of developing
disease.
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